Remove Heart Failure Remove Medicare Remove Quality of Life
article thumbnail

PO-03-162 REAL-WORLD TREATMENT PATHWAYS AND OUTCOMES IN A MEDICARE POPULATION WITH SINUS NODE DYSFUNCTION AND HEART FAILURE WITH PRESERVED EJECTION FRACTION

HeartRhythm

Guidelines recommend permanent pacemaker (PPM) implantation in patients with sinus node dysfunction (SND) to improve quality of life. Patients with heart failure with preserved ejection fraction (HFpEF) have many comorbidities including SND, but the optimal treatment approach for HFpEF with SND is uncertain.

article thumbnail

BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes

DAIC

Although prognosis of refractory angina has improved in recent years, patients with refractory angina experience a significantly impaired quality of life with disproportionately high utilization of healthcare services. These observations reflect the great need for new therapies for these patients.

article thumbnail

From the Member Sections | Tackling the Polypharmacy Pandemic in CV Care

American College of Cardiology

Initiatives such as the World Health Organization's "Medication Without Harm" and the Centers for Medicare and Medicaid Services' (CMS) expanded quality measures aim to reduce preventable emergency visits and hospital admissions due to medication-related harm. had one or more severe potential drug-drug interaction.1 BMC Med2015;13(74).

article thumbnail

Patient Enrollment Commenced in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of Ischemic Heart Failure

DAIC

BioCardia previously confirmed alignment with the United States Food and Drug Administration (FDA) on the design of the 250-patient randomized, controlled trial and the minimum of 12-month primary composite endpoint of all cause death, reduction in major adverse cardiovascular events, and improvement in quality of life.

article thumbnail

BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

DAIC

CMS has reviewed the CardiAMP Heart Failure II Trial and approved the investigational product, related and routine items and services for purposes of Medicare coverage. The CardiAMP Heart Failure II Trial is FDA approved to enroll up to 250 patients at up to 40 clinical centers. said Peter Altman , PhD.,

CMS 111
article thumbnail

Published Research

Society of Thoracic Surgeons - Research

Adult Cardiac Surgery Database Lead Author Title Publication Date Jacob Raphael Red Blood Cell Transfusion and Pulmonary Complications: The Society of Thoracic Surgeons Adult Cardiac Surgery Database Analysis The Annals of Thoracic Surgery January 2024 Joseph Sabik Multi-Arterial versus Single-Arterial Coronary Surgery: Ten Year Follow-up of One Million (..)

article thumbnail

Published Research

Society of Thoracic Surgeons - Research

Program Designations Access and Publications (A&P) 1 Participant User File (PUF) 2 Task Force on Funded Research (TFR) 3 Special Projects 4 Adult Cardiac Surgery Database Lead Author Title Publication Date William Keeling 2 National Trends in Emergency Coronary Artery Bypass Grafting European Journal of Cardiothoracic Surgery October 2023 Jake (..)